Z-LEHD-fmk Options
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Major trial objectives had been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis ind